Sanofi to launch HIB shot in Japan

Sanofi Pasteur says it's poised to enter the Japanese market with its ActHIB vaccine that targets Haemophilius influenza type b; the shot will be marketed there by Daiichi-Sankyo and will be available beginning next month. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.